Uricemin is developed by University of Pavia.

What development phase is Uricemin in?

Uricemin is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Uricemin

University of Pavia · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Uricemin
Sponsor	University of Pavia
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Nutraceutical on Hyperuricemia (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Uricemin CI brief — competitive landscape report
Uricemin updates RSS · CI watch RSS
University of Pavia portfolio CI